Given cDC1 differentiation is interrupted in cancer, our study shows that there is no longer a sufficient supply of cDC1 progenitors available to populate new and persistent sites of inflammation, such as sites of tumor outgrowth and metastasis, and that this lack of cDC1s is detrimental to anti-tumor CD8+ T-cell responses. This evidence concerns the gene MPPE1 and neoplasm.